1. CELG needs the disputed patent rights to develope its five other drugs.
2. CYCC's sapacitabine is likely to become the ideal drug for treating AML, MDS, and Solid Tumors due to its efficacy, safety, and in oral form.
3. The tiny market cap of CYCC would be a cheap buy.
It now presents the great oppotinity for CELG to acquire CYCC. It will grab it with no hestation.
There always is an inflection point in biotech stocks like CYCC. I believe we are very close. Clearly, institutional interest is rising. Looking forward to the march report. Should be very interesting indeed.
i doubt it... if sap is so valuable cycc would not give it away and we wouldnt have a $5 stock and a 52 million market cap... something doesnt seem right here... cycc shoulkd already have a 200+ miliion market cap if drug had potential///
Right now the stock is stuck in a narrow trading range.....Any positive news will initiate a breakout. The event that everyone is waiting to hear about is whether or not there will be a settlement. If there's no settlement, the pps could drop below $5.00 for a short period. If CELG agrees to pay 50 million dollars (unlikely however), we could see a new high.